Get started
● Optimal Entry: Look for buying opportunities near or at $56, a key support level where recent price action suggests an attractive risk-reward opportunity.
● Downside Protection: Set a stop loss at $46.50 to limit potential losses in case of adverse price movements.
● Upside Target: The primary profit-taking zone is $74, offering a 32% return from the entry point.
● Dominance in a high-growth market: Novo Nordisk is a leader in the rapidly expanding markets for diabetes and obesity treatments. The company's flagship products Wegovy and Ozempic are central to its success, with the obesity care segment seeing a 56% sales increase in the first half of 2025. The global markets for obesity and diabetes are projected to grow significantly, with over a billion people living with obesity worldwide, leaving a large underserved patient population.
● Strong and innovative drug pipeline: The healthcare giant has a strong pipeline of next-generation therapies aimed at maintaining its market leadership. Key future products include an oral version of semaglutide for obesity, expected to launch in early 2026, which could potentially improve patient compliance. Another promising candidate is CagriSema, which has shown significant weight loss in trials and is expected to be filed for regulatory approval in 2026.
● Strategic & financial health: Despite facing challenges from competitors like Eli Lilly and the sale of compounded drug alternatives, the company maintains a strong financial position. The company has a formidable 32.6% global diabetes market share. Furthermore, Novo Nordisk is making strategic moves to secure its future, including a $16.5 billion acquisition of Catalent to scale up manufacturing.
● Test of major support: The share price has retraced to the crucial $48 support region. This level is historically significant, representing a price floor established in 2022. A retest of such a major support zone often acts as a potential turning point, as buyers who previously found value at this price may re-enter the market. The stock's ability to hold above this level is critical for a potential bullish reversal.
● Bullish momentum signal: A key positive signal is emerging from the Moving Average Convergence Divergence (MACD) indicator. A bullish crossover has occurred, where the MACD line has crossed above its signal line. This suggests that the downward momentum is fading and that a shift towards positive momentum is underway.
● Bullish reversal pattern: The price action has formed a falling wedge pattern. This is a classic technical formation characterised by two converging, downward-sloping trendlines. A falling wedge typically appears during a downtrend and signals that selling pressure is diminishing, leading to a potential breakout to the upside. The narrowing of the price range within the wedge indicates a consolidation period before a potential sharp move.
● Overreliance on a narrow product portfolio: A portion of Novo Nordisk's recent growth and current valuation is tied to the success of its Ozempic and Wegovy. This heavy reliance on a single class of drugs makes the company's cash flow and stock price vulnerable to shifts in competition, patent challenges or unforeseen safety issues with these specific products.
● Litigation and side effect risks: As the use of Wegovy and Ozempic has become widespread, reports of serious side effects have emerged, leading to a growing number of lawsuits. Patients have filed claims alleging that the drugs caused severe gastrointestinal issues like gastroparesis (stomach paralysis), gallbladder problems and vision loss. While the long-term health impacts are still being studied, this litigation represents a significant financial and reputational risk for the company.
Disclaimer:
* This article was prepared by BROKSTOCK analyst Maboko Seabi
**Any opinions, views, analysis, or other information provided in this article is provided by BROKSTOCK SA trading as BROKSTOCK as general market commentary and should not be viewed as advice according to the FAIS Act of 2002. BROKSTOCK SA does not warrant the correctness, accuracy, timeliness, reliability, or completeness of any information provided by third parties. You must rely upon your judgement in all aspects of your investment decisions, and all decisions are made at your own risk. BROKSTOCK SA and any of its employees shall not be responsible for and will not accept any liability for any direct or indirect loss, including, without limitation, any loss of profit which may arise directly or indirectly from the use of the market commentary. The content contained within the article is subject to change at any time without notice. BROKSTOCK SA is an authorised financial services provider - FSP No. 51404. T&Cs and Disclaimers are applicable: https://brokstock.co.za/
